Comparison of the efficacy and safety of neoadjuvant PD-1 inhibitors plus chemotherapy vs targeted therapy plus chemotherapy in locally advanced hypopharyngeal squamous cell carcinoma
PD-1 inhibitors combined with chemotherapy showed better short-term efficacy compared to targeted therapy. Additionally, a trend toward improved long-term survival was observed with PD-1 inhibitors but not with targeted therapy. Results for both groups indicate that neoadjuvant therapy is both safe and manageable.
Authors
- Gaofei Yin (ORCID: https://orcid.org/0000-0002-9828-7139)
- Lifei Feng (ORCID: https://orcid.org/0009-0004-7775-6209)
- Duoxuan Chen
- Wen Gao
- Yang Zhang
- Xiaohong Chen (ORCID: https://orcid.org/0000-0002-9797-8384)
- Zishi Huang
- Jugao Fang (ORCID: https://orcid.org/0000-0001-7375-424X)
- Li Zhao (ORCID: https://orcid.org/0000-0002-7703-5397)
- Qi Zhong (ORCID: https://orcid.org/0000-0003-1259-5200)
- Zhigang Huang (ORCID: https://orcid.org/0000-0002-9173-1743)
- Wei Guo (ORCID: https://orcid.org/0009-0000-0457-9070)
Institutions
- Beijing Tongren Hospital (CN)
- Capital Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-31
- DOI
- https://doi.org/10.3389/fimmu.2024.1466310
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- National Natural Science Foundation of China
- Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support
- Beijing Municipal Administration of Hospitals